Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin vs Dapagliflozin in Type 2 Diabetes
NCT03202563Phase 4Completed
- Sponsor
- LG Chem
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoint: Mean Amplitude of Glycemic Excursion at 12 weeks. Started Aug 2017; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03202563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202563.